|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COPG2 |
Gene summary for COPG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COPG2 | Gene ID | 26958 |
| Gene name | COPI coat complex subunit gamma 2 | |
| Gene Alias | 2-COP | |
| Cytomap | 7q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9NSM7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26958 | COPG2 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.10e-03 | 4.17e-01 | -0.1088 |
| 26958 | COPG2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.76e-09 | 5.88e-01 | -0.1954 |
| 26958 | COPG2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.29e-02 | 2.81e-01 | -0.1464 |
| 26958 | COPG2 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.30e-07 | 4.77e-01 | -0.1001 |
| 26958 | COPG2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.63e-03 | 4.60e-01 | -0.059 |
| 26958 | COPG2 | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.87e-04 | 6.97e-01 | -0.0177 |
| 26958 | COPG2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.34e-24 | 7.59e-01 | 0.0674 |
| 26958 | COPG2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.47e-03 | 3.35e-01 | 0.294 |
| 26958 | COPG2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.64e-20 | 1.15e+00 | 0.281 |
| 26958 | COPG2 | A015-C-203 | Human | Colorectum | FAP | 4.72e-03 | -1.78e-01 | -0.1294 |
| 26958 | COPG2 | A002-C-205 | Human | Colorectum | FAP | 3.60e-03 | -1.69e-01 | -0.1236 |
| 26958 | COPG2 | A015-C-006 | Human | Colorectum | FAP | 3.53e-02 | -2.19e-01 | -0.0994 |
| 26958 | COPG2 | A002-C-114 | Human | Colorectum | FAP | 3.41e-04 | -2.54e-01 | -0.1561 |
| 26958 | COPG2 | A015-C-104 | Human | Colorectum | FAP | 4.21e-04 | -2.41e-01 | -0.1899 |
| 26958 | COPG2 | A002-C-116 | Human | Colorectum | FAP | 2.67e-03 | -2.15e-01 | -0.0452 |
| 26958 | COPG2 | A018-E-020 | Human | Colorectum | FAP | 1.20e-04 | -2.37e-01 | -0.2034 |
| 26958 | COPG2 | LZE4T | Human | Esophagus | ESCC | 3.08e-02 | 1.63e-01 | 0.0811 |
| 26958 | COPG2 | LZE7T | Human | Esophagus | ESCC | 4.54e-04 | 2.98e-01 | 0.0667 |
| 26958 | COPG2 | LZE20T | Human | Esophagus | ESCC | 1.09e-02 | 1.88e-01 | 0.0662 |
| 26958 | COPG2 | LZE24T | Human | Esophagus | ESCC | 6.53e-11 | 2.78e-01 | 0.0596 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00355923 | Colorectum | FAP | establishment of protein localization to extracellular region | 79/2622 | 360/18723 | 2.48e-05 | 5.77e-04 | 79 |
| GO:00716923 | Colorectum | FAP | protein localization to extracellular region | 79/2622 | 368/18723 | 5.50e-05 | 1.10e-03 | 79 |
| GO:00307053 | Colorectum | FAP | cytoskeleton-dependent intracellular transport | 47/2622 | 195/18723 | 1.06e-04 | 1.76e-03 | 47 |
| GO:00068904 | Colorectum | FAP | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 18/2622 | 52/18723 | 1.48e-04 | 2.29e-03 | 18 |
| GO:00723841 | Colorectum | FAP | organelle transport along microtubule | 22/2622 | 85/18723 | 2.66e-03 | 2.07e-02 | 22 |
| GO:00068884 | Colorectum | FAP | endoplasmic reticulum to Golgi vesicle-mediated transport | 30/2622 | 130/18723 | 3.51e-03 | 2.53e-02 | 30 |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
| GO:000689017 | Esophagus | ESCC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 46/8552 | 52/18723 | 1.23e-10 | 3.66e-09 | 46 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
| GO:00723846 | Esophagus | ESCC | organelle transport along microtubule | 65/8552 | 85/18723 | 6.61e-09 | 1.35e-07 | 65 |
| GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
| GO:00068914 | Esophagus | ESCC | intra-Golgi vesicle-mediated transport | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COPG2 | SNV | Missense_Mutation | rs782187967 | c.290N>A | p.Thr97Asn | p.T97N | Q9UBF2 | protein_coding | tolerated(0.51) | benign(0.005) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| COPG2 | SNV | Missense_Mutation | c.234A>C | p.Gln78His | p.Q78H | Q9UBF2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| COPG2 | SNV | Missense_Mutation | c.724N>C | p.Glu242Gln | p.E242Q | Q9UBF2 | protein_coding | deleterious(0.02) | possibly_damaging(0.644) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| COPG2 | SNV | Missense_Mutation | rs372285287 | c.2606C>A | p.Ser869Tyr | p.S869Y | Q9UBF2 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COPG2 | SNV | Missense_Mutation | rs782187967 | c.290N>A | p.Thr97Asn | p.T97N | Q9UBF2 | protein_coding | tolerated(0.51) | benign(0.005) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COPG2 | SNV | Missense_Mutation | rs782187967 | c.290N>A | p.Thr97Asn | p.T97N | Q9UBF2 | protein_coding | tolerated(0.51) | benign(0.005) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COPG2 | SNV | Missense_Mutation | novel | c.2275N>C | p.Asp759His | p.D759H | Q9UBF2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
| COPG2 | SNV | Missense_Mutation | c.421N>A | p.Glu141Lys | p.E141K | Q9UBF2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| COPG2 | insertion | Frame_Shift_Ins | novel | c.84dupA | p.Gln29ThrfsTer8 | p.Q29Tfs*8 | Q9UBF2 | protein_coding | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR | ||
| COPG2 | SNV | Missense_Mutation | c.28N>A | p.Glu10Lys | p.E10K | Q9UBF2 | protein_coding | deleterious(0) | benign(0.223) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |